NO995823L - Terapeutisk middel for ereksjonsdysfunksjon - Google Patents

Terapeutisk middel for ereksjonsdysfunksjon

Info

Publication number
NO995823L
NO995823L NO995823A NO995823A NO995823L NO 995823 L NO995823 L NO 995823L NO 995823 A NO995823 A NO 995823A NO 995823 A NO995823 A NO 995823A NO 995823 L NO995823 L NO 995823L
Authority
NO
Norway
Prior art keywords
therapeutic agent
erectile dysfunction
erectile
dysfunction
therapeutic
Prior art date
Application number
NO995823A
Other languages
English (en)
Norwegian (no)
Other versions
NO995823D0 (no
Inventor
Tatsuto Notsu
Nobuo Ohzawa
Yasuhiro Nakai
Original Assignee
Mochida Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharm Co Ltd filed Critical Mochida Pharm Co Ltd
Publication of NO995823D0 publication Critical patent/NO995823D0/no
Publication of NO995823L publication Critical patent/NO995823L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO995823A 1997-05-29 1999-11-26 Terapeutisk middel for ereksjonsdysfunksjon NO995823L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4029797P 1997-05-29 1997-05-29
JP34413497 1997-11-29
PCT/JP1998/002378 WO1998053819A1 (fr) 1997-05-29 1998-05-29 Agent therapeutique destine a traiter l'anerection

Publications (2)

Publication Number Publication Date
NO995823D0 NO995823D0 (no) 1999-11-26
NO995823L true NO995823L (no) 2000-01-28

Family

ID=26577702

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995823A NO995823L (no) 1997-05-29 1999-11-26 Terapeutisk middel for ereksjonsdysfunksjon

Country Status (9)

Country Link
EP (1) EP0992240A4 (de)
KR (1) KR20010012995A (de)
CN (1) CN1309561A (de)
AU (1) AU739417B2 (de)
BR (1) BR9809508A (de)
CA (1) CA2291256A1 (de)
IL (1) IL132993A0 (de)
NO (1) NO995823L (de)
WO (1) WO1998053819A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9810766B (en) 1997-11-28 1999-05-25 Mochida Pharm Co Ltd Novel compounds having cgmp-pde inhibitory activity
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
TWI223598B (en) * 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
US6200591B1 (en) * 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
WO2000032195A1 (fr) * 1998-12-02 2000-06-08 Mochida Pharmaceutical Co., Ltd. Preparations destinees a etre administrees par voie uretrale
GB9828340D0 (en) * 1998-12-22 1999-02-17 Novartis Ag Organic compounds
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
JP2002539165A (ja) * 1999-03-16 2002-11-19 ペンテツク・フアーマシユーテイカルズ・インコーポレイテツド 舌下またはバッカル投与により送出されるシルデナフィルの制御放出
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
CA2391968A1 (en) * 1999-11-18 2001-05-25 Natco Pharma Limited An improved pharmaceutical composition for treating male erectile dysfunction
DE10010612A1 (de) * 2000-03-03 2001-09-27 Merck Patent Gmbh Verwendung von PDE V-Inhibitoren
CN1436080A (zh) 2000-04-19 2003-08-13 利利艾科斯有限公司 环gmp-特异性磷酸二酯酶抑制剂治疗帕金森氏病的用途
WO2002005820A1 (en) * 2000-07-19 2002-01-24 Lavipharm Laboratories, Inc. Sildenafil citrate solid dispersions having high water solubility
DE10118306A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
WO2002102385A1 (en) * 2001-06-14 2002-12-27 Sampad Bhattacharya Compositions comprising cgmppde5 inhibitor for transdermal delivery to the erectile tissue of the penis
AU2003257289A1 (en) 2002-07-26 2004-02-16 Kenneth W. Adams Pharmaceutical compositions for penis enlargement
US7662831B2 (en) 2006-07-27 2010-02-16 Wyeth Llc Tetracyclic indoles as potassium channel modulators
CN101429166B (zh) * 2007-11-07 2013-08-21 上海特化医药科技有限公司 喹唑啉酮衍生物及其制备方法和用途
EP2526926A1 (de) * 2011-05-25 2012-11-28 Justus-Liebig-Universität Gießen Biokompatible Nanopolymerpartikel mit Wirkstoffen für die pulmonale Applikation
RU2618462C2 (ru) * 2011-12-26 2017-05-03 Тритек Биофармасьютикалз Ко., Лтд. Способ и улучшенная фармацевтическая композиция для ускорения трансдермальной доставки ингибитора pde-5
US20170035764A1 (en) * 2015-08-03 2017-02-09 Synergistic Therapeutics, Llc Sexual dysfunction therapeutic gel
JP6865933B2 (ja) 2018-02-23 2021-04-28 株式会社Meis Technology 勃起不全治療剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
KR100374924B1 (ko) * 1994-04-22 2003-07-22 퀸스 유니버시티 엣 킹스톤 남성발기기능장애를회복시키고진단하기위한설하용량형
EP0985671B1 (de) * 1996-05-31 2003-04-02 Mochida Pharmaceutical Co., Ltd. PYRIDOCARBAZOL DERIVATE DIE EINEN cGMP-PDE INHIBILIERENDEN EFFEKT HABEN
GB9612514D0 (en) * 1996-06-14 1996-08-14 Pfizer Ltd Novel process

Also Published As

Publication number Publication date
KR20010012995A (ko) 2001-02-26
IL132993A0 (en) 2001-03-19
EP0992240A1 (de) 2000-04-12
AU7454898A (en) 1998-12-30
CN1309561A (zh) 2001-08-22
BR9809508A (pt) 2000-06-20
AU739417B2 (en) 2001-10-11
EP0992240A4 (de) 2003-04-16
NO995823D0 (no) 1999-11-26
CA2291256A1 (en) 1998-12-03
WO1998053819A1 (fr) 1998-12-03

Similar Documents

Publication Publication Date Title
NO995823D0 (no) Terapeutisk middel for ereksjonsdysfunksjon
ID22834A (id) Pirazolopimidinona untuk kelainan seksual
IS2494B (is) Notkun á morfólínóli til meðhöndlunar á kynferðislegri vanvirkni
NO992806D0 (no) Terapeutiske midler
GB9905010D0 (en) Therapeutic agents
NO20022692D0 (no) Terapeutiske midler
ID27841A (id) Turunan-turunan biaril terapeutik
NO980546D0 (no) Farmasöytiske midler
GB9904786D0 (en) Therapeutic agents
GB9929685D0 (en) Therapeutic agents
GB9929687D0 (en) Therapeutic agents
NO20005179D0 (no) Medikament behandling
NO990805L (no) Middel for ereksjonssvikt omfattende kondenserte pyridazinforbindelser
GB9911881D0 (en) Therapeutic agents
GB9921351D0 (en) Therapeutic agents
NO20000969D0 (no) Ftalazinderivater og midler for erektil dysfunksjon
NO20001196D0 (no) Nootropisk middel
GB9903476D0 (en) Therapeutic agents
GB9914744D0 (en) Therapeutic agents
NO20012226D0 (no) Terapeutiske midler for medikamentavhengighet
IS5814A (is) Ný lyfjafræðileg notkun á NOS lötum
NO20016301D0 (no) Terapeutiske midler
GB9914745D0 (en) Therapeutic agents
GB9902881D0 (en) Therapeutic agents
ES1041026Y (es) Vibrador terapeutico.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application